Instil Bio, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Instil Bio, Inc. (TIL) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$69.02 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-27
- Instil Bio, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$69.02M.
- Instil Bio, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$60.38M.
- Instil Bio, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$144.57M.
- Instil Bio, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$183.99M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$69.02M 10-K · filed 2026-03-27 |
| 2024-12-31 | -$60.38M 10-K · filed 2026-03-27 |
| 2023-12-31 | -$144.57M 10-K · filed 2025-03-04 |
| 2022-12-31 | -$183.99M 10-K · filed 2024-03-21 |
| 2021-12-31 | -$154.78M 10-K · filed 2023-03-31 |
| 2020-12-31 | -$38.65M 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |